Levtock 250mg Tablet contains Levetiracetam 250mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and preventing seizure propagation. It is commonly prescribed as adjunctive therapy in adults and pediatric patients aged one month and older. Levtock is well-absorbed orally, with rapid onset of action and minimal drug interactions, making it suitable for monotherapy or combination therapy. The dosage should be individualized based on clinical response and tolerability, with gradual titration to minimize adverse effects. Common side effects include somnolence, dizziness, headache, and fatigue, while serious adverse reactions are rare but may include behavioral changes or hypersensitivity reactions. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Levtock 250mg Tablet should be used under medical supervision, with regular monitoring to assess efficacy and safety. Patients are advised not to discontinue therapy abruptly to avoid increased seizure risk. This medication is contraindicated in individuals with known hypersensitivity to Levetiracetam or any tablet components.